This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 23.34% and 11.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil
Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.
5 S&P 500 Stocks to Buy Ahead of Q3 Earnings This Week
by Nalak Das
Five big S&P 500 companies (market capital > $45 billion) are slated to release third-quarter earnings results this week. These are: COF, DXCM, XOM, AFL and TMO.
Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases
by Zacks Equity Research
Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.
Why Thermo Fisher (TMO) Might Surprise This Earnings Season
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Healthcare, AST and Life Sciences segments is driving the top line for STERIS (STE).
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $608.41, moving +0.46% from the previous trading session.
Top Stock Reports for Alphabet, Netflix & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Netflix, Inc. (NFLX), and Thermo Fisher Scientific Inc. (TMO).
Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust customer uptake and novel innovations are likely to have contributed to growth for Teladoc (TDOC).
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) Receives EUA from FDA for Latest Assay
by Zacks Equity Research
PerkinElmer's (PKI) latest test receives EUA from the FDA, thereby enabling qualified laboratories to detect and differentiate SARS-CoV-2, influenza A, influenza B and RSV.
Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow
by Zacks Equity Research
Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.
Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $577.35, moving +0.66% from the previous trading session.
BD's (BDX) Rotarex Atherectomy System Gets FDA 510 (k) Clearance
by Zacks Equity Research
BD's (BDX) Rotarex Atherectomy System receives expanded 510 (k) clearance from the FDA that can help in the treatment of in-stent restenosis in the United States.
Edwards Lifesciences (EW) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Improvement in Critical Care and Surgical Structural Heart businesses is expected to have contributed to Edwards Lifesciences' (EW) third-quarter results.
COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings
by Zacks Equity Research
In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DEF
PerkinElmer's (PKI) Arm Gets FDA EUA Nod for Latest Assay
by Zacks Equity Research
PerkinElmer's (PKI) unit receives FDA's EUA nod for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG) that could aid in future understanding and provide insights on immune responses to SARS-CoV-2.
Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher's (TMO) recent launches within Chromatography and Mass Spectrometry like Thermo Scientific Orbitrap IQ-X Tribrid Mass Spectrometer should have contributed to its Q3 top line.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher (TMO) Boosts COVID Testing With Wastewater Kit
by Zacks Equity Research
Thermo Fisher's (TMO) wastewater surveillance method is set to identify asymptomatic carriers on college campuses to monitor regional spread among communities.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.